Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides

被引:24
|
作者
Roth, CM [1 ]
机构
[1] Rutgers State Univ, Dept Chem & Biochem Engn, Dept Biomed Engn, Piscataway, NJ 08854 USA
关键词
D O I
10.1529/biophysj.104.054080
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Antisense oligonucleotides present a powerful means to inhibit expression of specific genes, but their effectiveness is limited by factors including cellular delivery, biochemical attack, and poor binding to target. We have developed a systems model of the processes required for an antisense oligonucleotide to enter, gain access to its target mRNA, and exert activity in a cell. The model accurately mimics observed trends in antisense effectiveness with the stability of the oligonucleotide backbone and with the affinity/kinetics of binding to the mRNA over the time course of inhibition. By varying the model parameters within the physically realizable range, we note that the major molecular and cellular barriers to antisense effectiveness are intracellular trafficking, oligonucleotide-mRNA binding rate, and nuclease degradation of oligonucleotides, with a weaker dependence on total cellular uptake than might be expected. Furthermore, the model may serve as a predictive tool to design and test strategies for the cellular use of antisense oligonucleotides. The use of integrated mathematical modeling can play a significant role in the development of antisense and related technologies.
引用
收藏
页码:2286 / 2295
页数:10
相关论文
共 50 条
  • [41] Cellular Delivery and Biological Activity of Antisense Oligonucleotides Conjugated to a Targeted Protein Carrier
    Kang, Hyunmin
    Alam, Md. Rowshon
    Dixit, Vidula
    Fisher, Michael
    Juliano, Rudy L.
    BIOCONJUGATE CHEMISTRY, 2008, 19 (11) : 2182 - 2188
  • [42] Effect of pluronic on cellular uptake of cationic liposomes-mediated antisense oligonucleotides
    Chen, HL
    Hu, QH
    Liang, WQ
    PHARMAZIE, 2004, 59 (02): : 131 - 133
  • [43] Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis
    Ming, Xin
    EXPERT OPINION ON DRUG DELIVERY, 2011, 8 (04) : 435 - 449
  • [44] ANTISENSE OLIGONUCLEOTIDES - STEREOCONTROLLED SYNTHESIS OF PHOSPHOROTHIOATE OLIGONUCLEOTIDES
    SUSKA, A
    GRAJKOWSKI, A
    WILK, A
    UZNANSKI, B
    BLASZCZYK, J
    WIECZOREK, M
    STEC, WJ
    PURE AND APPLIED CHEMISTRY, 1993, 65 (04) : 707 - 714
  • [45] The influence of target protein half-life on the effectiveness of antisense oligonucleotides.
    Giles, RV
    Spiller, DG
    Broughton, CM
    Grzybowski, J
    Ruddell, CJ
    Tidd, DM
    Clark, RE
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 58 - 58
  • [46] ANTISENSE OLIGONUCLEOTIDES - FROM TOOLS IN MOLECULAR-GENETICS TO THERAPEUTIC AGENTS
    TOULME, JJ
    VERSPIEREN, P
    BOIZIAU, C
    LOREAU, N
    CAZENAVE, C
    THUONG, NT
    ANNALES DE PARASITOLOGIE HUMAINE ET COMPAREE, 1990, 65 : 11 - 14
  • [47] Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
    Wang, Dali
    Wang, Qiwei
    Wang, Yuyan
    Chen, Peiru
    Lu, Xueguang
    Jia, Fei
    Sun, Yehui
    Sun, Tingyu
    Zhang, Lei
    Che, Fangyuan
    He, Jialu
    Lian, Liming
    Morano, Gemma
    Shen, Michael
    Ren, Mengqi
    Dong, Sijia S.
    Zhao, Jean J.
    Zhang, Ke
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (29)
  • [48] Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?
    Li, Dunhui
    Mastaglia, Frank L.
    Yau, Wai Yan
    Chen, Shengdi
    Wilton, Steve D.
    Akkari, Patrick A.
    MOVEMENT DISORDERS, 2022, 37 (11) : 2184 - 2190
  • [49] High-molecular weight polyethylene glycols conjugated to antisense oligonucleotides
    Bonora, GM
    BIOMEDICAL POLYMERS AND POLYMER THERAPEUTICS, 2001, : 371 - 387
  • [50] RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
    Bennett, C. Frank
    Swayze, Eric E.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 : 259 - 293